



Gender Medicine and Pharmacology

Guest Editors:

Dr. Sarah Allegra

Department of Biological and Clinical Sciences, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy

Dr. Silvia De Francia

Department of Biological and Clinical Sciences, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy

Deadline for manuscript submissions:
closed (25 August 2022)

Message from the Guest Editors

Regarding sex, differences in pathophysiology, disease incidence, drug pharmacodynamics/kinetics, response to treatment and related toxicity have been reported. However, several clinical trials have reported an underrepresentation of women, and, in clinical settings, data regarding sex are rarely reported. In women, factors such as body size and composition, hormonal variations, metabolism and access to care systems and therapy could strongly influence pharmacological management and treatment outcomes. In terms of the incidence and prevalence of many diseases, differences between the two sexes play an important role in terms of risk factors. The application of a gender approach from the beginning should be a pivotal tool to optimize treatment in each patient, for each condition.

The Special Issue “Gender medicine and pharmacology” will focus on differences at the molecular, cellular and genetic levels in terms of incidence, pathology, physiology and treatment between genders: male, female and genderfluid people. This Special Issue is open for basic to clinical research, or multi-disciplinary approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)